Arya Consulting Partners announced the release of The Orphan Advantage: How Rare Disease Assets Are Redefining Biopharma Deal Strategy, the third installment in the firm’s Rare Disease white paper series.
The white paper examines how rare disease assets have shifted from niche opportunities to strategic anchors within biopharmaceutical portfolios. As internal R&D productivity declines and the industry faces a historic patent cliff, the analysis highlights why large pharmaceutical companies are increasingly turning to orphan and specialty assets to drive sustainable growth.
The Orphan Advantage explores how rare disease assets offer a more predictable commercial trajectory, how business development and licensing behavior has evolved, and what factors now drive both buy‑side and sell‑side decisions. The paper also provides forward‑looking insights into how rare disease BD&L strategies are expected to evolve over the next decade.
This publication continues Arya Consulting Partners’ commitment to delivering data‑driven perspectives that help biopharma leaders navigate complexity, manage risk, and build resilient portfolios in an increasingly volatile market environment.
Get expert analysis, industry trends, and exclusive updates delivered straight to your inbox. Stay ahead of the curve with valuable insights that drive success.
